Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 77

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 77
---
 Clinical Trial                                |     | $       | 150,000 |
| Upon First patient enrolled in a Phase II Clinical Trial                               |     | $       | 300,000 |
| Upon First patient enrolled in a Phase III Clinical Trial                              |     | $       | 450,000 |
| Upon First Commercial Sale in either Europe or the US, the earlier to occur of the two |     | $       | 600,000 |

Research and Option Agreement with Yissum

On October 25, 2023, we entered into Research and Option Agreement with Yissum with respect to the nanoparticles-based formulation of angiotensin receptor blockers (ARB) for intravenous administration. Under agreement, we shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation, preparation and characterization of nanoparticles-based formulation of angiotensin receptor blockers (ARB) for intravenous administration. In consideration for the research services, we agreed to pay research service fees of $150,000, in periodic payments subject to completing specified milestones. All data generated from the provision of the services, including any reports, which are specifically required and contemplated under such agreement, shall be owned by us upon full payment of the research services fees. Each party will be entitled to terminate the agreement in the event of a breach by the other party of its obligations under the agreement, including, but not limited to, any payment failure, which is not remedied by the breaching party within 30 days of receipt of written notice from the non-breaching party.

Subject to receiving a final report as to the results of the research, we have the exclusive right to enter into a license agreement substantially on terms above. The research is continuing.

Our Growth Strategy

The Company plans to recruit an in-house development team, with members working on several projects simultaneously to save costs and maximize knowledge and expertise. Where relevant stages of the process will be subcontracted, with members of our team supervising their work.

We aim to progress with the continuous research and developments activities, to develop additional applications using its technologies and to develop future product candidatesand the necessary clinical trials until such time as they can be commercialized through licensing to larger pharmaceutical companies which will take responsibility for completing advanced stages CTs trials, like Phase III and obtaining regulatory approvals and marketing the products.

In connection with our Development of Nano Mupirocin, we are planning to:

| ● | Conduct                                                                                           
 a clinical development of Nano Mupirocin in collaboration with the National Institute